Humanin: A Novel Central Regulator of Peripheral Insulin Action
Open Access
- 22 July 2009
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (7), e6334
- https://doi.org/10.1371/journal.pone.0006334
Abstract
Decline in insulin action is a metabolic feature of aging and is involved in the development of age-related diseases including Type 2 Diabetes Mellitus (T2DM) and Alzheimer's disease (AD). A novel mitochondria-associated peptide, Humanin (HN), has a neuroprotective role against AD-related neurotoxicity. Considering the association between insulin resistance and AD, we investigated if HN influences insulin sensitivity. Using state of the art clamp technology, we examined the role of central and peripheral HN on insulin action. Continuous infusion of HN intra-cerebro-ventricularly significantly improved overall insulin sensitivity. The central effects of HN on insulin action were associated with activation of hypothalamic STAT-3 signaling; effects that were negated by co-inhibition of hypothalamic STAT-3. Peripheral intravenous infusions of novel and potent HN derivatives reproduced the insulin-sensitizing effects of central HN. Inhibition of hypothalamic STAT-3 completely negated the effects of IV HN analog on liver, suggesting that the hepatic actions of HN are centrally mediated. This is consistent with the lack of a direct effect of HN on primary hepatocytes. Furthermore, single treatment with a highly-potent HN analog significantly lowered blood glucose in Zucker diabetic fatty rats. Based upon the link of HN with two age-related diseases, we examined if there were age associated changes in HN levels. Indeed, the amount of detectable HN in hypothalamus, skeletal muscle, and cortex was decreased with age in rodents, and circulating levels of HN were decreased with age in humans and mice. We conclude that the decline in HN with age could play a role in the pathogenesis of age-related diseases including AD and T2DM. HN represents a novel link between T2DM and neurodegeneration and along with its analogues offers a potential therapeutic tool to improve insulin action and treat T2DM.Keywords
This publication has 41 references indexed in Scilit:
- RETRACTED: S14G-Humanin ameliorates Aβ25-35-induced behavioral deficits by reducing neuroinflammatory responses and apoptosis in miceNeuropeptides, 2008
- Expression of the cytokine leukemia inhibitory factor and pro-apoptotic insulin-like growth factor binding protein-3 in Alzheimer's diseaseActa Neuropathologica, 2002
- Humanin inhibits cell death of serum-deprived PC12h cellsNeuroReport, 2002
- Evidence for in vivo production of Humanin peptide, a neuroprotective factor against Alzheimer's disease-related insultsNeuroscience Letters, 2002
- Detailed Characterization of Neuroprotection by a Rescue Factor Humanin against Various Alzheimer's Disease-Relevant InsultsJournal of Neuroscience, 2001
- [Gly14]‐Humanin improved the learning and memory impairment induced by scopolamine in vivoBritish Journal of Pharmacology, 2001
- Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell TransformationJournal of Biological Chemistry, 2001
- The adipocyte-secreted protein Acrp30 enhances hepatic insulin actionNature Medicine, 2001
- A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and AβProceedings of the National Academy of Sciences, 2001
- Glycemic modulation of insulin/IGF-1 mediated skeletal muscle blood following sympathetic denervation in normal rats.Clinical and Experimental Hypertension, 1999